Increased PD-1 expression on CD4+ and CD8+ T cells is involved in immune evasion in gastric cancer

Journal of Surgical Oncology

Volumn 107, Issue 5, 2013, Pages 517-522

  Saito, Hiroaki ^a   Kuroda, Hirohiko ^a   Matsunaga, Tomoyuki ^a   Osaki, Tomohiro ^a   Ikeguchi, Masahide ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

gastric cancer; PD 1; PD L1; T cell

Indexed keywords

GAMMA INTERFERON; PROGRAMMED DEATH 1 RECEPTOR;

AGED; ARTICLE; CANCER PATIENT; CANCER TISSUE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNE EVASION; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER; STOMACH MUCOSA; UPREGULATION;

AGED; ANTIGENS, CD14; CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; FLOW CYTOMETRY; HUMANS; INTERFERON-GAMMA; MALE; MONOCYTES; PROGRAMMED CELL DEATH 1 RECEPTOR; STOMACH NEOPLASMS; UP-REGULATION;

EID: 84875241223     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23281     Document Type: Article

References (38)

1. Urban JL, Schreiber H,: Tumor antigens. Annu Rev Immunol 1992; 10: 617-644.
2. Chen L,: Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 2004; 4: 336-347.
3. Greenwald RJ, Freeman GJ, Sharpe AH,: The B7 family revisited. Annu Rev Immunol 2005; 23: 515-548.
4. Sharpe AH, Wherry EJ, Ahmed R, et al.: The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat Immunol 2007; 8: 239-245.
5. Freeman GJ, Long AJ, Iwai Y, et al.: Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000; 192: 1027-1034.
6. Dong H, Zhu G, Tamada K, et al.: B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999; 5: 1365-1369.
7. Tseng SY, Otsuji M, Gorski K, et al.: B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J Exp Med 2001; 193: 839-846.
8. Latchman Y, Wood CR, Chernova T, et al.: PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001; 2: 261-268.
9. Keir ME, Freeman GJ, Sharpe AH,: PD-1 regulates self-reactive CD8+ T cell responses to antigen in lymph nodes and tissues. J Immunol 2007; 179: 5064-5070.
10. Nishimura H, Okazaki T, Tanaka Y, et al.: Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 2001; 291: 319-322.
11. Nishimura H, Nose M, Hiai H, et al.: Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999; 11: 141-151.
12. Blank C, Brown I, Peterson AC, et al.: PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res 2004; 64: 1140-1145.
13. Curiel TJ, Wei S, Dong H, et al.: Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 2003; 9: 562-567.
14. Hirano F, Kaneko K, Tamura H, et al.: Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 2005; 65: 1089-1096.
15. Strome SE, Dong H, Tamura H, et al.: B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res 2003; 63: 6501-6505.
16. Dong H, Strome SE, Salomao DR, et al.: Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat Med 2002; 8: 793-800.
17. Iwai Y, Ishida M, Tanaka Y, et al.: Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 2002; 99: 12293-12297.
18. Thompson RH, Gillett MD, Cheville JC, et al.: Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci USA 2004; 101: 17174-17179.
19. Hamanishi J, Mandai M, Iwasaki M, et al.: Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci USA 2007; 104: 3360-3365.
20. Inman BA, Sebo TJ, Frigola X, et al.: PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: Associations with localized stage progression. Cancer 2007; 109: 1499-1505.
21. Wu C, Zhu Y, Jiang J, et al.: Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance. Acta Histochem 2006; 108: 19-24.
22. Nomi T, Sho M, Akahori T, et al.: Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res 2007; 13: 2151-2157.
23. Xu T, Shu CT, Purdom E, et al.: Microarray analysis reveals differences in gene expression of circulating CD8(+) T cells in melanoma patients and healthy donors. Cancer Res 2004; 64: 3661-3667.
24. Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, et al.: Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci USA 2010; 107: 7875-7880.
25. Parkin DM, Bray F, Ferlay J, et al.: Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
26. Inoue H, Mori M, Honda M, et al.: The expression of tumor-rejection antigen "MAGE" genes in human gastric carcinoma. Gastroenterology 1995; 109: 1522-1525.
27. Hoshino T, Seki N, Kikuchi M, et al.: HLA class-I-restricted and tumor-specific CTL in tumor-infiltrating lymphocytes of patients with gastric cancer. Int J Cancer 1997; 70: 631-638.
28. Japanese Gastric Cancer Association: Japanese Classification of Gastric Carcinoma - 2nd English Edition. Gastric Cancer 1998; 1: 10-24.
29. Barber DL, Wherry EJ, Masopust D, et al.: Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006; 439: 682-687.
30. Keir ME, Butte MJ, Freeman GJ, et al.: PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008; 26: 677-704.
31. Brown JA, Dorfman DM, Ma FR, et al.: Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol 2003; 170: 1257-1266.
32. Dong H, Chen L,: B7-H1 pathway and its role in the evasion of tumor immunity. J Mol Med (Berl) 2003; 81: 281-287.
33. Ikeguchi M, Hatada T, Yamamoto M, et al.: Serum interleukin-6 and -10 levels in patients with gastric cancer. Gastric Cancer 2009; 12: 95-100.
34. Sakamoto T, Saito H, Tatebe S, et al.: Interleukin-10 expression significantly correlates with minor CD8+ T-cell infiltration and high microvessel density in patients with gastric cancer. Int J Cancer 2006; 118: 1909-1914.
35. Kryczek I, Zou L, Rodriguez P, et al.: B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med 2006; 203: 871-881.
36. Kuang DM, Zhao Q, Peng C, et al.: Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1. J Exp Med 2009; 206: 1327-1337.
37. Melero I, Hervas-Stubbs S, Glennie M, et al.: Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 2007; 7: 95-106.
38. Hodi FS, O'Day SJ, McDermott DF, et al.: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723.